Aequus Pharmaceuticals Inc. AEQ.F Stock
Aequus Pharmaceuticals Inc. Price Chart
Aequus Pharmaceuticals Inc. AEQ.F Financial and Trading Overview
| Aequus Pharmaceuticals Inc. stock price | 0.0040 EUR |
| Previous Close | 0.02 EUR |
| Open | 0.02 EUR |
| Bid | 0.01 EUR x 0 |
| Ask | 0.04 EUR x 0 |
| Day's Range | 0.02 - 0.02 EUR |
| 52 Week Range | 0.0068 - 0.07 EUR |
| Volume | 20K EUR |
| Avg. Volume | 5.87K EUR |
| Market Cap | 1.99M EUR |
| Beta (5Y Monthly) | 0.624338 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.01 EUR |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
AEQ.F Valuation Measures
| Enterprise Value | 4.81M EUR |
| Trailing P/E | N/A |
| Forward P/E | N/A |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 1.7008095 |
| Price/Book (mrq) | N/A |
| Enterprise Value/Revenue | 4.109 |
| Enterprise Value/EBITDA | -1.983 |
Trading Information
Aequus Pharmaceuticals Inc. Stock Price History
| Beta (5Y Monthly) | 0.624338 |
| 52-Week Change | -26.53% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 0.07 EUR |
| 52 Week Low | 0.0068 EUR |
| 50-Day Moving Average | 0.01 EUR |
| 200-Day Moving Average | 0.02 EUR |
AEQ.F Share Statistics
| Avg. Volume (3 month) | 5.87K EUR |
| Avg. Daily Volume (10-Days) | 18K EUR |
| Shares Outstanding | 132.63M |
| Float | 112.79M |
| Short Ratio | N/A |
| % Held by Insiders | 14.96% |
| % Held by Institutions | 0% |
| Shares Short | N/A |
| Short % of Float | N/A |
| Short % of Shares Outstanding | N/A |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | -259.67% |
| Operating Margin (ttm) | -207.82% |
| Gross Margin | 88.64% |
| EBITDA Margin | -207.24% |
Management Effectiveness
| Return on Assets (ttm) | -67.40% |
| Return on Equity (ttm) | N/A |
Income Statement
| Revenue (ttm) | 1.17M EUR |
| Revenue Per Share (ttm) | 0.009 EUR |
| Quarterly Revenue Growth (yoy) | -69.50% |
| Gross Profit (ttm) | N/A |
| EBITDA | -2424175 EUR |
| Net Income Avi to Common (ttm) | -3037481 EUR |
| Diluted EPS (ttm) | -0.04 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 44.18K EUR |
| Total Cash Per Share (mrq) | 0 EUR |
| Total Debt (mrq) | 2.86M EUR |
| Total Debt/Equity (mrq) | N/A |
| Current Ratio (mrq) | 0.086 |
| Book Value Per Share (mrq) | -0.016 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -2103769 EUR |
| Levered Free Cash Flow (ttm) | -1274203 EUR |
Profile of Aequus Pharmaceuticals Inc.
| Country | Germany |
| State | BC |
| City | Vancouver |
| Address | 200 Granville Street |
| ZIP | V6C 1S4 |
| Phone | N/A |
| Website | https://www.aequuspharma.ca |
| Industry | Drug Manufacturers-Specialty & Generic |
| Sector(s) | Healthcare |
| Full Time Employees | 12 |
Aequus Pharmaceuticals Inc., a specialty pharmaceutical company, develops and commercializes drugs in Canada. It focuses on various therapeutic areas, including neurology, ophthalmology, and transplantation. The company markets Vistitan, an ophthalmology product to reduce elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Tacrolimus IR, an immunosuppressant for the treatment and prevention of acute rejection following organ transplantation; Evolve dry eye products for various symptoms involved with dry eye disease and blepharitis, including discomfort, stinging, burning, and dryness; and preservative free ophthalmic product. Its development stage product includes Topiramate XR and Oxcarbazepine XR extended-release oral tablets for the treatment of epilepsy; AQS1303, a transdermal pyridoxine/doxylamine for the treatment of nausea and vomiting of pregnancy; and AQS1304, a cannabinoid based therapeutics for neurological disorders. The company has collaboration agreements with Sandoz Canada, Inc. for the promotion of Vistitan; Supernus Pharmaceuticals, Inc. for marketing of extended-release anti-epileptic drugs; and Medicom Healthcare Ltd. to focus on preservative free therapies in ophthalmology. Aequus Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in Vancouver, Canada.
Q&A For Aequus Pharmaceuticals Inc. Stock
What is a current AEQ.F stock price?
Aequus Pharmaceuticals Inc. AEQ.F stock price today per share is 0.0040 EUR.
How to purchase Aequus Pharmaceuticals Inc. stock?
You can buy AEQ.F shares on the Frankfurt exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Aequus Pharmaceuticals Inc.?
The stock symbol or ticker of Aequus Pharmaceuticals Inc. is AEQ.F.
Which industry does the Aequus Pharmaceuticals Inc. company belong to?
The Aequus Pharmaceuticals Inc. industry is Drug Manufacturers-Specialty & Generic.
How many shares does Aequus Pharmaceuticals Inc. have in circulation?
The max supply of Aequus Pharmaceuticals Inc. shares is 448.18M.
What is Aequus Pharmaceuticals Inc. Price to Earnings Ratio (PE Ratio)?
Aequus Pharmaceuticals Inc. PE Ratio is now.
What was Aequus Pharmaceuticals Inc. earnings per share over the trailing 12 months (TTM)?
Aequus Pharmaceuticals Inc. EPS is -0.01 EUR over the trailing 12 months.
Which sector does the Aequus Pharmaceuticals Inc. company belong to?
The Aequus Pharmaceuticals Inc. sector is Healthcare.